Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

267
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
267
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

220
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
220
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

443
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
443
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

334
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
334
Gene Therapy00:59

Gene Therapy

27.7K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.7K
Group Therapy01:26

Group Therapy

454
Group therapy is a sociocultural approach to psychological treatment, where individuals with shared psychological challenges come together under the guidance of a mental health professional. This therapeutic modality offers unique opportunities for individuals to connect, share, and grow within the context of a supportive group. By fostering mutual understanding and collaboration, group therapy can address a range of psychological concerns effectively, often complementing or surpassing the...
454

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Living in the Borderlands Between Electrophysiology and Cardiomyopathy.

JACC. Case reports·2026
Same author

Catheter ablation of atrial fibrillation in transthyretin and light-chain cardiac amyloidosis: results from the multicentre AMYL-AF study.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

Inflammation in Cardiomyopathies: Cellular Mechanisms Across Cardiac Phenotype.

Cells·2026
Same author

Personalized Sudden Cardiac Death Risk Stratification in Hypertrophic Cardiomyopathy: Beyond Conventional Risk Scores.

Journal of personalized medicine·2026
Same author

Incidental Diagnosis of TTR Amyloidosis During Left Bundle Branch Pacing Implantation: When Electrophysiology Meets Cardiomyopathy.

JACC. Case reports·2026
Same author

Deep Phenotyping of F64L Mutation in a Multicentric Cohort of Patisiran-Treated Hereditary Transthyretin Amyloidosis Patients (Patisiranitaly).

European journal of neurology·2026

Related Experiment Video

Updated: Feb 10, 2026

Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis
06:39

Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis

Published on: October 27, 2023

1.5K

Immunosuppressive therapy in myocarditis.

Andrea Frustaci1, Cristina Chimenti

  • 1Cardiovascular, Respiratory, Nefrologic, Geriatric and Anestesiologic Sciences Department, La Sapienza University, Rome; IRCCS L.Spallanzani, Italy. biocard@inmi.it

Circulation Journal : Official Journal of the Japanese Circulation Society
|December 3, 2014
PubMed
Summary

Immunosuppression effectively treats virus-negative inflammatory cardiomyopathy (ICM), improving heart function in most patients. Some cases may involve unidentifiable viruses or inflammation resistant to this therapy.

More Related Videos

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.5K
Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse
12:24

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse

Published on: June 20, 2014

10.5K

Related Experiment Videos

Last Updated: Feb 10, 2026

Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis
06:39

Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis

Published on: October 27, 2023

1.5K
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.5K
Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse
12:24

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse

Published on: June 20, 2014

10.5K

Area of Science:

  • Cardiology
  • Immunology
  • Pathology

Background:

  • The therapeutic role of immunosuppression in lymphocytic inflammatory cardiomyopathy (ICM) remains debated.
  • Previous studies suggest benefit in virus-negative ICM but not virus-positive ICM.
  • Cardiomyocyte HLA upregulation may indicate ICM susceptibility to immunosuppression.

Purpose of the Study:

  • To evaluate the efficacy of immunosuppression in virus-negative inflammatory cardiomyopathy (ICM).

Main Methods:

  • A randomized, double-blind, placebo-controlled trial (TIMIC study) was conducted.
  • 85 virus-negative ICM patients received prednisone and azathioprine plus supportive care or placebo.
  • Left ventricular ejection fraction and dimensions were assessed.

Main Results:

  • 88% of treated patients showed improved left ventricular ejection fraction and reduced dimensions.
  • 83% of placebo patients experienced cardiac impairment.
  • 12% of treated patients did not respond, suggesting alternative mechanisms.

Conclusions:

  • Immunosuppression is effective in virus-negative ICM, improving cardiac function.
  • Non-response may indicate unidentifiable viruses or non-immunosuppressive inflammatory pathways.
  • Responders showed reduced cardiomyocyte death and increased proliferation.